Exebryl-1

Exebryl-1 is an orally bioavailable small-molecule amyloid- and tau-directed agent developed by ProteoTech as a potential disease-modifying therapy for Alzheimer’s disease, designed to prevent the formation, deposition, and accumulation of soluble and insoluble beta-amyloid species and to disaggregate existing amyloid plaques in the brain.[1][2][5][7][9][11] Preclinical data showed that Exebryl-1 reduces cerebral beta-amyloid load by approximately 30–50% in transgenic Alzheimer’s mouse models with associated memory improvement, and it also inhibits tau protein aggregation into paired helical filaments, targeting both amyloid plaques and neurofibrillary tangles.[1][5][7][9] The compound advanced into Phase 1 human clinical trials for mild-to-moderate Alzheimer’s disease and has also been identified in screening campaigns as a non-redox-reactive small-molecule inhibitor of the SARS-CoV-2 nsp15 endoribonuclease with modest antiviral activity, highlighting its potential as a chemical starting point for antiviral optimization.[1][3][10][12][13]

Other names

Exebryl-1Exebryl1Exebryl 1